-
1
-
-
60749128400
-
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials
-
COI: 1:CAS:528:DC%2BD1MXisVSksr8%3D, PID: 19211452
-
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. JNCI J Natl Cancer Inst. 2009;101(4):256–66.
-
(2009)
JNCI J Natl Cancer Inst
, vol.101
, Issue.4
, pp. 256-266
-
-
Cole, B.F.1
Logan, R.F.2
Halabi, S.3
Benamouzig, R.4
Sandler, R.S.5
Grainge, M.J.6
-
2
-
-
84880278340
-
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial
-
PID: 23856681, This study reports long-term follow-up data from the Women’s Health Study. Importantly, it shows that long-term follow-up is necessary to detect the anti-cancer effects of aspirin
-
Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77–85. This study reports long-term follow-up data from the Women’s Health Study. Importantly, it shows that long-term follow-up is necessary to detect the anti-cancer effects of aspirin.
-
(2013)
Ann Intern Med
, vol.159
, Issue.2
, pp. 77-85
-
-
Cook, N.R.1
Lee, I.M.2
Zhang, S.M.3
Moorthy, M.V.4
Buring, J.E.5
-
3
-
-
78650215449
-
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
-
COI: 1:CAS:528:DC%2BC3cXhsVGitbfF, PID: 20970847
-
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.
-
(2010)
Lancet
, vol.376
, Issue.9754
, pp. 1741-1750
-
-
Rothwell, P.M.1
Wilson, M.2
Elwin, C.E.3
Norrving, B.4
Algra, A.5
Warlow, C.P.6
-
4
-
-
80053994835
-
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
-
COI: 1:CAS:528:DC%2BC3MXhtlahsrvM, PID: 21847126
-
Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–13.
-
(2011)
Br J Cancer
, vol.105
, Issue.8
, pp. 1107-1113
-
-
Langley, R.E.1
Burdett, S.2
Tierney, J.F.3
Cafferty, F.4
Parmar, M.K.5
Venning, G.6
-
5
-
-
84876404642
-
-
Langley RE. Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience. 2013;(7). This review gives an update on the evidence supporting aspirin use in the adjuvant setting
-
Langley RE. Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience. 2013;(7). This review gives an update on the evidence supporting aspirin use in the adjuvant setting.
-
-
-
-
6
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
-
PID: 19482214
-
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
-
(2009)
Lancet
, vol.373
, Issue.9678
, pp. 1849-1860
-
-
Baigent, C.1
Blackwell, L.2
Collins, R.3
Emberson, J.4
Godwin, J.5
Peto, R.6
-
7
-
-
84925537586
-
Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population
-
COI: 1:CAS:528:DC%2BC2cXitVers7bP, PID: 25421783, This is the most recent systematic review of the harms of aspirin use in the general population, and describes potential strategies to mitigate the risks of adverse effects
-
Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol. 2015;30(1):5–18. This is the most recent systematic review of the harms of aspirin use in the general population, and describes potential strategies to mitigate the risks of adverse effects.
-
(2015)
Eur J Epidemiol
, vol.30
, Issue.1
, pp. 5-18
-
-
Thorat, M.A.1
Cuzick, J.2
-
8
-
-
0026572734
-
Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis
-
COI: 1:CAS:528:DyaK38Xktl2qtr0%3D, PID: 1315625
-
Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis. 1992;13(4):541–6.
-
(1992)
Carcinogenesis
, vol.13
, Issue.4
, pp. 541-546
-
-
Craven, P.A.1
DeRubertis, F.R.2
-
9
-
-
0027183769
-
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
-
COI: 1:CAS:528:DyaK3sXmtFKqsr4%3D, PID: 8353834
-
Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993;14(8):1493–7.
-
(1993)
Carcinogenesis
, vol.14
, Issue.8
, pp. 1493-1497
-
-
Reddy, B.S.1
Rao, C.V.2
Rivenson, A.3
Kelloff, G.4
-
10
-
-
0031958067
-
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin
-
COI: 1:CAS:528:DyaK1cXjtVSjsro%3D, PID: 9558273
-
Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 1998;114(5):873–7.
-
(1998)
Gastroenterology
, vol.114
, Issue.5
, pp. 873-877
-
-
Barnes, C.J.1
Lee, M.2
-
11
-
-
0023687241
-
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study
-
COI: 1:STN:280:DyaL1c3ntVequg%3D%3D, PID: 3390835
-
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399–404.
-
(1988)
Cancer Res
, vol.48
, Issue.15
, pp. 4399-4404
-
-
Kune, G.A.1
Kune, S.2
Watson, L.F.3
-
12
-
-
84861722871
-
Aspirin and cancer risk: a quantitative review to 2011
-
COI: 1:STN:280:DC%2BC38rmsFWhtQ%3D%3D, PID: 22517822
-
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–15.
-
(2012)
Ann Oncol
, vol.23
, Issue.6
, pp. 1403-1415
-
-
Bosetti, C.1
Rosato, V.2
Gallus, S.3
Cuzick, J.4
La Vecchia, C.5
-
13
-
-
79960059582
-
Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort
-
COI: 1:CAS:528:DC%2BC3MXos1Kjurk%3D, PID: 21407185
-
Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106(7):1340–50.
-
(2011)
Am J Gastroenterol
, vol.106
, Issue.7
, pp. 1340-1350
-
-
Ruder, E.H.1
Laiyemo, A.O.2
Graubard, B.I.3
Hollenbeck, A.R.4
Schatzkin, A.5
Cross, A.J.6
-
14
-
-
84940481188
-
-
Ann Intern Med: This is the most recent study supporting the role of aspirin in the prevention of colorectal cancer
-
Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Ann Intern Med. 2015. This is the most recent study supporting the role of aspirin in the prevention of colorectal cancer.
-
(2015)
A Population-Based, Case-Control Study
-
-
Friis, S.1
Riis, A.H.2
Erichsen, R.3
Baron, J.A.4
Use, U.5
Risk, C.C.6
-
15
-
-
83955161674
-
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
-
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2012;378(9809):2081–7.
-
(2012)
Lancet
, vol.378
, Issue.9809
, pp. 2081-2087
-
-
Burn, J.1
Gerdes, A.M.2
Macrae, F.3
Mecklin, J.P.4
Moeslein, G.5
Olschwang, S.6
-
16
-
-
84947265874
-
-
Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. J Clin Oncol. 2015. This sub-analysis of the CAPP2 trial shows that obesity may identify those who stand to benefit most from aspirin use in those with Lynch syndrome
-
Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. J Clin Oncol. 2015. This sub-analysis of the CAPP2 trial shows that obesity may identify those who stand to benefit most from aspirin use in those with Lynch syndrome.
-
-
-
-
17
-
-
79955832527
-
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis
-
COI: 1:CAS:528:DC%2BC3MXnslektL8%3D
-
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655–65.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, Issue.5
, pp. 655-665
-
-
Burn, J.1
Bishop, D.T.2
Chapman, P.D.3
Elliott, F.4
Bertario, L.5
Dunlop, M.G.6
-
18
-
-
2542536944
-
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs
-
COI: 1:CAS:528:DC%2BD2cXksVKntLo%3D, PID: 15173100
-
Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, et al. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004;10(11):3908–18.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.11
, pp. 3908-3918
-
-
Kelloff, G.J.1
Schilsky, R.L.2
Alberts, D.S.3
Day, R.W.4
Guyton, K.Z.5
Pearce, H.L.6
-
19
-
-
84891449924
-
-
J Natl Cancer Inst, This recent study reported that a particular SNP may identify those who benefit from aspirin use for the chemoprevention of colorectal cancer
-
Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin Use, 8q24 Single Nucleotide Polymorphism rs6983267, and Colorectal Cancer According to CTNNB1 Alterations. J Natl Cancer Inst. 2013. This recent study reported that a particular SNP may identify those who benefit from aspirin use for the chemoprevention of colorectal cancer.
-
(2013)
Aspirin Use, 8q24 Single Nucleotide Polymorphism rs6983267, and Colorectal Cancer According to CTNNB1 Alterations
-
-
Nan, H.1
Morikawa, T.2
Suuriniemi, M.3
Imamura, Y.4
Werner, L.5
Kuchiba, A.6
-
20
-
-
84929390853
-
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants
-
COI: 1:CAS:528:DC%2BC2MXlvVWmsrY%3D, PID: 25781442, This recent study reports that two further single-nucleotide polymorphisms may identify those who benefit from aspirin use for the chemoprevention of colorectal cancer
-
Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313(11):1133–42. This recent study reports that two further single-nucleotide polymorphisms may identify those who benefit from aspirin use for the chemoprevention of colorectal cancer.
-
(2015)
JAMA
, vol.313
, Issue.11
, pp. 1133-1142
-
-
Nan, H.1
Hutter, C.M.2
Lin, Y.3
Jacobs, E.J.4
Ulrich, C.M.5
White, E.6
-
21
-
-
0036735391
-
Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells
-
COI: 1:CAS:528:DC%2BD38Xmslylurc%3D, PID: 12208739
-
Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002;62(17):4903–8.
-
(2002)
Cancer Res
, vol.62
, Issue.17
, pp. 4903-4908
-
-
Tang, X.1
Sun, Y.J.2
Half, E.3
Kuo, M.T.4
Sinicrope, F.5
-
22
-
-
0030002547
-
Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines
-
COI: 1:CAS:528:DyaK28XivF2rur4%3D, PID: 8625297
-
Elder DJ, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res. 1996;56(10):2273–6.
-
(1996)
Cancer Res
, vol.56
, Issue.10
, pp. 2273-2276
-
-
Elder, D.J.1
Hague, A.2
Hicks, D.J.3
Paraskeva, C.4
-
23
-
-
84963793679
-
-
Gastroenterology, This case-control study utilising UK General Practice data does not show the trend seen in other studies towards an improvement in colorectal cancer outcomes with aspir
-
Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, et al. Low-dose Aspirin Use After Diagnosis of Colorectal Cancer Does not Increase Survival: a Case-Control Analysis of a Population-Based Cohort. Gastroenterology. 2013. This case-control study utilising UK General Practice data does not show the trend seen in other studies towards an improvement in colorectal cancer outcomes with aspirin use.
-
(2013)
Low-dose Aspirin Use After Diagnosis of Colorectal Cancer Does not Increase Survival: a Case-Control Analysis of a Population-Based Cohort
-
-
Cardwell, C.R.1
Kunzmann, A.T.2
Cantwell, M.M.3
Hughes, C.4
Baron, J.A.5
Powe, D.G.6
-
24
-
-
68849123400
-
Aspirin use and survival after diagnosis of colorectal cancer
-
COI: 1:CAS:528:DC%2BD1MXpslynu7w%3D, PID: 19671906
-
Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58.
-
(2009)
JAMA
, vol.302
, Issue.6
, pp. 649-658
-
-
Chan, A.T.1
Ogino, S.2
Fuchs, C.S.3
-
25
-
-
84963889633
-
-
Bains S, Mahic M, Cvancarova M, Yaqub S, Dørum ML, Bjørnbeth BA, et al. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: a population-based study. J Clin Oncol 2015;33(suppl; abstr 3504)
-
Bains S, Mahic M, Cvancarova M, Yaqub S, Dørum ML, Bjørnbeth BA, et al. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: a population-based study. J Clin Oncol 2015;33(suppl; abstr 3504).
-
-
-
-
26
-
-
84860250352
-
Use of aspirin postdiagnosis improves survival for colon cancer patients
-
COI: 1:CAS:528:DC%2BC38Xmt1Ghu7c%3D, PID: 22454078
-
Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–70.
-
(2012)
Br J Cancer
, vol.106
, Issue.9
, pp. 1564-1570
-
-
Bastiaannet, E.1
Sampieri, K.2
Dekkers, O.M.3
de Craen, A.J.4
van Herk-Sukel, M.P.5
Lemmens, V.6
-
27
-
-
84874938572
-
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality
-
COI: 1:CAS:528:DC%2BC38XhslSmu7fE, PID: 23182687
-
McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49(5):1049–57.
-
(2013)
Eur J Cancer
, vol.49
, Issue.5
, pp. 1049-1057
-
-
McCowan, C.1
Munro, A.J.2
Donnan, P.T.3
Steele, R.J.4
-
28
-
-
84926518325
-
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer
-
PID: 25432409, This is the most recent study to suggest that aspirin has a role in the adjuvant treatment of cancer
-
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107(1):345. This is the most recent study to suggest that aspirin has a role in the adjuvant treatment of cancer.
-
(2015)
J Natl Cancer Inst
, vol.107
, Issue.1
, pp. 345
-
-
Ng, K.1
Meyerhardt, J.A.2
Chan, A.T.3
Sato, K.4
Chan, J.A.5
Niedzwiecki, D.6
-
29
-
-
84867897314
-
Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study
-
COI: 1:CAS:528:DC%2BC38XhsFOntLnE, PID: 23011483
-
Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107(9):1602–7.
-
(2012)
Br J Cancer
, vol.107
, Issue.9
, pp. 1602-1607
-
-
Walker, A.J.1
Grainge, M.J.2
Card, T.R.3
-
30
-
-
84863399038
-
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
-
COI: 1:CAS:528:DC%2BC38XktlGku7c%3D, PID: 22440947
-
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.
-
(2012)
Lancet
, vol.379
, Issue.9826
, pp. 1591-1601
-
-
Rothwell, P.M.1
Wilson, M.2
Price, J.F.3
Belch, J.F.4
Meade, T.W.5
Mehta, Z.6
-
31
-
-
0037096879
-
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis
-
COI: 1:CAS:528:DC%2BD38XkslWqsb4%3D, PID: 12067981
-
Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 2002;62(12):3395–401.
-
(2002)
Cancer Res
, vol.62
, Issue.12
, pp. 3395-3401
-
-
Tiano, H.F.1
Loftin, C.D.2
Akunda, J.3
Lee, C.A.4
Spalding, J.5
Sessoms, A.6
-
32
-
-
84860386459
-
The role of aspirin in cancer prevention
-
COI: 1:CAS:528:DC%2BC38XmtlGgurc%3D, PID: 22473097
-
Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259–67.
-
(2012)
Nat Rev Clin Oncol
, vol.9
, Issue.5
, pp. 259-267
-
-
Thun, M.J.1
Jacobs, E.J.2
Patrono, C.3
-
33
-
-
84897978063
-
-
JAMA Intern Med: This recent study is the first to investigate the role of HLA class I expression on colorectal cancer outcomes in relation to aspir
-
Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA Class-I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer. JAMA Intern Med. 2014. This recent study is the first to investigate the role of HLA class I expression on colorectal cancer outcomes in relation to aspirin use.
-
(2014)
Expression of HLA Class-I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer
-
-
Reimers, M.S.1
Bastiaannet, E.2
Langley, R.E.3
van Eijk, R.4
van Vlierberghe, R.L.5
Lemmens, V.E.6
-
34
-
-
82955212867
-
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin
-
COI: 1:CAS:528:DC%2BC3MXht1yktL3L, PID: 21728052
-
Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130(2):657–62.
-
(2011)
Breast Cancer Res Treat
, vol.130
, Issue.2
, pp. 657-662
-
-
Holmes, M.D.1
Chen, W.Y.2
Schnitt, S.J.3
Collins, L.4
Colditz, G.A.5
Hankinson, S.E.6
-
35
-
-
84855893130
-
Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells
-
COI: 1:CAS:528:DC%2BC38Xos1Kluw%3D%3D, PID: 22127925
-
Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8.
-
(2012)
Cancer Res
, vol.72
, Issue.2
, pp. 440-448
-
-
Placke, T.1
Orgel, M.2
Schaller, M.3
Jung, G.4
Rammensee, H.G.5
Kopp, H.G.6
-
36
-
-
84867817838
-
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
-
COI: 1:CAS:528:DC%2BC38Xhs1Whsr3K, PID: 23094721
-
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606.
-
(2012)
N Engl J Med
, vol.367
, Issue.17
, pp. 1596-1606
-
-
Liao, X.1
Lochhead, P.2
Nishihara, R.3
Morikawa, T.4
Kuchiba, A.5
Yamauchi, M.6
-
37
-
-
84892843686
-
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer
-
COI: 1:CAS:528:DC%2BC3sXhvF2kur7J, PID: 24062397, This study investigated the role of PIK3CA mutation status on colorectal cancer outcomes and was the first to corroborate the effect seen in the study by Liao et.al
-
Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–305. This study investigated the role of PIK3CA mutation status on colorectal cancer outcomes and was the first to corroborate the effect seen in the study by Liao et.al.
-
(2013)
J Clin Oncol
, vol.31
, Issue.34
, pp. 4297-4305
-
-
Domingo, E.1
Church, D.N.2
Sieber, O.3
Ramamoorthy, R.4
Yanagisawa, Y.5
Johnstone, E.6
-
38
-
-
84925446564
-
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
-
COI: 1:CAS:528:DC%2BC2MXlsVShsL0%3D, PID: 25549537, This is the most recent study to investigate the effects of aspirin in PIK3CA mutant colorectal cancer. No significant improvement in overall survival or cancer-specific survival was observed with aspirin use in those with PIK3CA-mutated colorectal cancer
-
Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015;54(4):487–92. This is the most recent study to investigate the effects of aspirin in PIK3CA mutant colorectal cancer. No significant improvement in overall survival or cancer-specific survival was observed with aspirin use in those with PIK3CA-mutated colorectal cancer.
-
(2015)
Acta Oncol
, vol.54
, Issue.4
, pp. 487-492
-
-
Kothari, N.1
Kim, R.2
Jorissen, R.N.3
Desai, J.4
Tie, J.5
Wong, H.L.6
-
39
-
-
84879395305
-
Aspirin use and risk of colorectal cancer according to BRAF mutation status
-
COI: 1:CAS:528:DC%2BC3sXhtFOgs7fL, PID: 23800934, This study examined the role of colorectal cancer BRAF mutation status in relation to aspirin use and found that users had a lower risk of developing a BRAF wild-type tumour
-
Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24):2563–71. This study examined the role of colorectal cancer BRAF mutation status in relation to aspirin use and found that users had a lower risk of developing a BRAF wild-type tumour.
-
(2013)
JAMA
, vol.309
, Issue.24
, pp. 2563-2571
-
-
Nishihara, R.1
Lochhead, P.2
Kuchiba, A.3
Jung, S.4
Yamauchi, M.5
Liao, X.6
-
40
-
-
0030798861
-
One hundred years of aspirin
-
COI: 1:STN:280:DyaK2svgs1ajtQ%3D%3D, PID: 9259670
-
Jack DB. One hundred years of aspirin. Lancet. 1997;350(9075):437–9.
-
(1997)
Lancet
, vol.350
, Issue.9075
, pp. 437-439
-
-
Jack, D.B.1
-
41
-
-
84963816946
-
-
Electronic Medicines Compendium (eMC) SPC aspirin tablets BP 75 mg. 2014
-
Electronic Medicines Compendium (eMC) SPC aspirin tablets BP 75 mg. 2014. http://www.medicines.org.uk/emc/medicine/26656/SPC.
-
-
-
-
42
-
-
84858078199
-
Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey
-
PID: 21093073
-
Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75.
-
(2012)
Int J Cardiol
, vol.156
, Issue.1
, pp. 69-75
-
-
Cayla, G.1
Collet, J.P.2
Silvain, J.3
Thiefin, G.4
Woimant, F.5
Montalescot, G.6
-
43
-
-
77956417776
-
Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin
-
COI: 1:CAS:528:DC%2BC3cXht1GjurnM, PID: 20659284
-
Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32(7):831–9.
-
(2010)
Aliment Pharmacol Ther
, vol.32
, Issue.7
, pp. 831-839
-
-
Fletcher, E.H.1
Johnston, D.E.2
Fisher, C.R.3
Koerner, R.J.4
Newton, J.L.5
Gray, C.S.6
-
44
-
-
35148859360
-
Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan
-
COI: 1:CAS:528:DC%2BD2sXhtVWqtbvP, PID: 17671743
-
Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med. 2007;20(3):373–8.
-
(2007)
Int J Mol Med
, vol.20
, Issue.3
, pp. 373-378
-
-
Arisawa, T.1
Tahara, T.2
Shibata, T.3
Nagasaka, M.4
Nakamura, M.5
Kamiya, Y.6
-
45
-
-
34547558049
-
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms
-
COI: 1:CAS:528:DC%2BD2sXhtVWqsr7K, PID: 17681167
-
Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465–71.
-
(2007)
Gastroenterology
, vol.133
, Issue.2
, pp. 465-471
-
-
Pilotto, A.1
Seripa, D.2
Franceschi, M.3
Scarcelli, C.4
Colaizzo, D.5
Grandone, E.6
-
46
-
-
10744225344
-
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use
-
COI: 1:CAS:528:DC%2BD2cXhsFOis7w%3D, PID: 14707031
-
Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2):205–8.
-
(2004)
Br J Pharmacol
, vol.141
, Issue.2
, pp. 205-208
-
-
Martinez, C.1
Blanco, G.2
Ladero, J.M.3
Garcia-Martin, E.4
Taxonera, C.5
Gamito, F.G.6
-
47
-
-
84963861409
-
-
US Preventative Services Task Force. Aspirin to Prevent Cardiovascular Disease and Cancer. 2016. Available from:
-
US Preventative Services Task Force. Aspirin to Prevent Cardiovascular Disease and Cancer. 2016. Available from: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/aspirin-to-prevent-cardiovascular-disease-and-cancer?ds=1&s=aspirin.
-
-
-
-
48
-
-
84890560949
-
Mechanisms of aspirin resistance
-
COI: 1:CAS:528:DC%2BC3sXhsVCltLrM, PID: 23993980
-
Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141(1):69–78.
-
(2014)
Pharmacol Ther
, vol.141
, Issue.1
, pp. 69-78
-
-
Floyd, C.N.1
Ferro, A.2
-
49
-
-
60049093774
-
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays
-
COI: 1:CAS:528:DC%2BD1MXhvFGmur0%3D, PID: 19232899
-
Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. J Am Coll Cardiol. 2009;53(8):667–77.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.8
, pp. 667-677
-
-
Santilli, F.1
Rocca, B.2
De Cristofaro, R.3
Lattanzio, S.4
Pietrangelo, L.5
Habib, A.6
-
50
-
-
80053165917
-
-
Aspirin resistance and compliance with therapy, Cardiovasc Ther
-
Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther. 2010.
-
(2010)
et al
-
-
Dawson, J.1
Quinn, T.2
Rafferty, M.3
Higgins, P.4
Ray, G.5
Lees, K.R.6
-
51
-
-
84863430537
-
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
-
COI: 1:CAS:528:DC%2BC38Xht1ChtbfJ, PID: 22471290
-
Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10(7):1220–30.
-
(2012)
J Thromb Haemost
, vol.10
, Issue.7
, pp. 1220-1230
-
-
Rocca, B.1
Santilli, F.2
Pitocco, D.3
Mucci, L.4
Petrucci, G.5
Vitacolonna, E.6
-
52
-
-
84905469071
-
-
Ann Oncol: This article extensively reviews the overall risk-benefit profile of aspirin for the primary prevention of colorectal cancer
-
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2014. This article extensively reviews the overall risk-benefit profile of aspirin for the primary prevention of colorectal cancer.
-
(2014)
Estimates of benefits and harms of prophylactic use of aspirin in the general population
-
-
Cuzick, J.1
Thorat, M.A.2
Bosetti, C.3
Brown, P.H.4
Burn, J.5
Cook, N.R.6
-
53
-
-
79952271992
-
Advances in clinical trial designs for predictive biomarker discovery and validation
-
Simon R. Advances in clinical trial designs for predictive biomarker discovery and validation. Curr Breast Cancer Rep. 2009;1(4):216–21.
-
(2009)
Curr Breast Cancer Rep
, vol.1
, Issue.4
, pp. 216-221
-
-
Simon, R.1
-
54
-
-
84918592217
-
Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer
-
PID: 25503181, This study assessed the effects of aspirin on colorectal cancer specific survival in a predominantly Asian population and found a trend towards benefit with aspirin use
-
Goh CH, Leong WQ, Chew MH, Pan YS, Tony LK, Chew L, et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res. 2014;34(12):7407–14. This study assessed the effects of aspirin on colorectal cancer specific survival in a predominantly Asian population and found a trend towards benefit with aspirin use.
-
(2014)
Anticancer Res
, vol.34
, Issue.12
, pp. 7407-7414
-
-
Goh, C.H.1
Leong, W.Q.2
Chew, M.H.3
Pan, Y.S.4
Tony, L.K.5
Chew, L.6
|